257 related articles for article (PubMed ID: 22796518)
1. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
2. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
3. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
4. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
5. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
6. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Leitch HA; Buckstein R; Shamy A; Storring JM
Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
8. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
List AF
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Wiernik PH
Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
[TBL] [Abstract][Full Text] [Related]
10. A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
Zeldis JB; Knight R; Hussein M; Chopra R; Muller G
Ann N Y Acad Sci; 2011 Mar; 1222():76-82. PubMed ID: 21434945
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes.
Castelli R; Cassin R; Cannavò A; Cugno M
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):1-7. PubMed ID: 23153925
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
13. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
15. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
17. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
20. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]